Study: NCT05703126

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Complete blood count
Description: Before and after each course of chemotherapy: Complete blood count with counting the number of erythrocytes, leukocytes, leukocyte formula, platelets, erythrocyte sedimentation rate.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Biochemical blood test
Description: Before and after each course of chemotherapy: Biochemical blood test with the determination of the amount of total protein, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, creatinine, urea, AlAT, AsAT, LDH, glucose, C-reactive protein, troponin T, proBNP.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Biochemical blood test
Description: Before and after each course of chemotherapy: Biochemical blood test with the determination of the amount of total protein, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, creatinine, urea, AlAT, AsAT, LDH, glucose, C-reactive protein, troponin T, proBNP.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Coagulogram
Description: Before and after each course of chemotherapy: Coagulogram parameters (fibrinogen, APTT, INR).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Coagulogram
Description: Before and after each course of chemotherapy: Coagulogram parameters (fibrinogen, APTT, INR).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Immunoenzymatic analysis of the level of endothelin-1, asymmetric dimethylarginine
Description: Before the start of the treatment and after each course of chemotherapy: Immunoenzymatic analysis of the level of endothelin-1, asymmetric dimethylarginine.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Immunoenzymatic analysis of the level of endothelin-1, asymmetric dimethylarginine
Description: Before the start of the treatment and after each course of chemotherapy: Immunoenzymatic analysis of the level of endothelin-1, asymmetric dimethylarginine.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Stress echocardiography with the definition of global longitudinal deformation of the myocardium
Description: Before the start of the treatment and after each course of chemotherapy: Stress echocardiography with the definition of global longitudinal deformation of the myocardium.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Stress echocardiography with the definition of global longitudinal deformation of the myocardium
Description: Before the start of the treatment and after each course of chemotherapy: Stress echocardiography with the definition of global longitudinal deformation of the myocardium.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Triplex scanning of neck vessels
Description: Before the start of the treatment and after each course of chemotherapy: Triplex scanning of neck vessels.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Triplex scanning of neck vessels
Description: Before the start of the treatment and after each course of chemotherapy: Triplex scanning of neck vessels.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Electrocardiography
Description: Before and after each course of chemotherapy: Electrocardiography.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Electrocardiography
Description: Before and after each course of chemotherapy: Electrocardiography.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound of the abdominal cavity (with calculation of the area of the spleen) and lymph nodes
Description: Before the start of the treatment and after each course of chemotherapy: Ultrasound of the abdominal cavity (with calculation of the area of the spleen) and lymph nodes.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound of the abdominal cavity (with calculation of the area of the spleen) and lymph nodes
Description: Before the start of the treatment and after each course of chemotherapy: Ultrasound of the abdominal cavity (with calculation of the area of the spleen) and lymph nodes.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cytogenetic examination of the bone marrow to determine genetic abnormalities.
Description: Before the start of the treatment: Cytogenetic examination of the bone marrow to determine genetic abnormalities.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cytogenetic examination of the bone marrow to determine genetic abnormalities.
Description: Before the start of the treatment: Cytogenetic examination of the bone marrow to determine genetic abnormalities.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cytological examination of bone marrow cells with cytochemical examination
Description: Before the start of the treatment and after each course of chemotherapy: Cytological examination of bone marrow cells with cytochemical examination.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cytological examination of bone marrow cells with cytochemical examination
Description: Before the start of the treatment and after each course of chemotherapy: Cytological examination of bone marrow cells with cytochemical examination.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Immunophenotypic examination of the bone marrow by flow cytometry
Description: Before the start of the treatment: Immunophenotypic examination of the bone marrow by flow cytometry.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Immunophenotypic examination of the bone marrow by flow cytometry
Description: Before the start of the treatment: Immunophenotypic examination of the bone marrow by flow cytometry.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Determination of the presence of a FLT3 mutation using the PCR Method
Description: Before the start of the treatment: Determination of the presence of a FLT3 mutation using the PCR Method.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Determination of the presence of a FLT3 mutation using the PCR Method
Description: Before the start of the treatment: Determination of the presence of a FLT3 mutation using the PCR Method.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: laser Doppler flowmetry
Description: Before the start of the treatment and after each course of chemotherapy: Examination of microcirculation by laser Doppler flowmetry using the LAKK-OP apparatus (NPP Lazma, Moscow, 2011) with respiratory and occlusion tests.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: laser Doppler flowmetry
Description: Before the start of the treatment and after each course of chemotherapy: Examination of microcirculation by laser Doppler flowmetry using the LAKK-OP apparatus (NPP Lazma, Moscow, 2011) with respiratory and occlusion tests.